CTRI/2016/04/006789已完成未知
An open-label, randomised, single-dose, three-way cross over, six sequence study to determine the relative bioavailability of clopidogrel 75mg from two tablet formulations of SB224326 relative to one 75mg reference tablet of clopidogrel in healthy adult human subjects under fasting conditions - Asian
GlaxoSmithKline Research and Development Limited0 个研究点目标入组 18 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •Adult subjects aged between 18 and 65 years of age inclusive at the time of signing the informed consent.
- •Healthy non-smoker as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.
- •A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the investigator in consultation with the Medical Monitor if required agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
- •Body weight >=50 kilograms (kg) and Body mass index (BMI) within the range 19 â?? 24.9 kg/square meter kg/m2 (inclusive)
- •Female subject: is eligible to participate if she is not pregnant (as confirmed by a negative serum human chorionic gonadotrophin [hCG] test), not lactating, and at least one of the following conditions applies.
- •Non-reproductive potential defined as
- •Pre-menopausal females with one of the following
- •Documented tubal ligation
- •Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion
- •Hysterectomy
- •Documented bilateral oophorectomy
- •Postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle stimulating hormone [FSH] and estradiol levels consistent with menopause [refer to laboratory reference ranges for confirmatory levels]). Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment
- •Reproductive potential and agrees to follow one of the options listed below in the GSK Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) requirements from 30 days prior to the first dose of study medication and until [at least five terminal half-lives OR until any continuing pharmacologic effect has ended, whichever is longer] after the last dose of study medication and completion of the follow-up visit.INFORMED CONSENT
- •Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
排除标准
- •Plavix contains lactose and subjects with lactose intolerance should not be included.
- •The QTc is the QT interval corrected for heart rate according to Bazettâ??s formula (QTcB), Fridericiaâ??s formula (QTcF), and/or another method, machineread or manually over-read
- •The following medications increase risk of bleeding: Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs).
- •History of sensitivity to heparin or heparin-induced thrombocytopenia
- •Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study treatment. For potent immunosuppressive agents, subjects with presence of hepatitis B core
研究者
相似试验
招募中
不适用
Relative bioavailability of montelukast sodium 5mg from two candidate chewable tablet formulations of GW483100 relative to one 5mg chewable tablet of reference montelukast sodium in healthy adult subjects under fasting conditionsCTRI/2015/03/005625GlaxoSmithKline Research and Development Limited18
已完成
不适用
Relative bioavailability study of two candidate formulations of GR107719B (Mosapride 5 mg) under fasting conditionsCTRI/2014/01/004318GlaxoSmithKline Research and Development Limited18
已完成
不适用
Relative bioavailability study of two candidate tablet formulations of 16mg candesartan cilexetil (GW615775) compared with the reference product Atacand (16mg candesartan cilexetil, AstraZeneca) in healthy human subjects under fasting conditionsCTRI/2014/12/005269GlaxoSmithKline Research and Development Limited18
已完成
不适用
A clinical trial to investigate the pharmacokinetic drug-drug interaction of Cilnidipine 10 mg and Valsartan 160 mg in healthy male volunteersKCT0000763Ildong pharmaceutical54
进行中（未招募）
不适用
Clinical study to test that the drug CHF 1535 100/6 (fixed combination of an anti-inflammatory drug and relaxing airways drug) delivered via pressurized inhaler using or not a spacer device is as effective in adolescent population as the licensed free combination of the same substances and compare it with administration in adults.MedDRA version: 14.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2011-005108-14-PLChiesi Farmaceutici S.p.A.